Aspirin resistance candidate genes and their association with the risk of fatal cardiovascular events


Cite item

Full Text

Abstract

The review presents the current data available in the world literature on the most likely gene polymorphisms, such as cyclooxygenase, glycoproteins (GP) Ib/IIIa, GP Ibα, GP VI, adenosine diphosphate receptor P2Y1 and P2Y12 polymorphisms that may lead to aspirin resistance. The frequency of these polymorphisms in laboratory aspirin resistance and their association with the development of adverse cardiovascular events from the use of aspirin are considered.

Full Text

Гены-кандидаты резистентности к ацетилсалициловой кислоте и их связь с риском развития фатальных сердечно-сосудистых осложнений. - Аннотация. В обзоре приведены современные данные мировой литературы о наиболее вероятных полиморфизмах генов, которые могут приводить к развитию резистентности к ацетилсалициловой кислоте (АСК; аспирину), таких как полиморфизмы генов циклооксигеназы, гликопротеинов GPIb/IIIa, GPIbα, GPVI, рецепторов P2Y1, P2Y12 к аденозиндифосфату. Рассмотрена распространенность полиморфизмов при лабораторной резистентности к АСК, связь данных полиморфизмов с развитием сердечно-сосудистых осложнений на фоне приема АСК.
×

References

  1. Baigent C., Blackwell L., Collins R. et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860.
  2. Krasopoulos G., Brister S. J., Beattie W. S. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-198.
  3. Snoep J. D., Hovens M. M., Eikenboom J. C. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007; 167 (15): 1593-1599.
  4. Cañivano Petreñas L., García Yubero C. Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review. Farm Hosp 2010; 34 (1): 32-43.
  5. Dussaillant G., Zapata M., Fardella P. et al. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chile 2005; 133 (4): 409-417.
  6. Friend M., Vucenik I., Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326 (7380): 82-83.
  7. Xu Z.H., Jiao J.R., Yang R. et al. Aspirin resistance: clinical significance and genetic polymorphism. J Int Med Res 2012; 40 (1): 282-292.
  8. Catella-Lawson F., Reilly M., Kapoor S. C. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
  9. Hankey G.J., Eikelboom J.W. Aspirin resistance. Lancet 2006; 367: 606-617.
  10. Mansour K., Taher A.T., Musallam K.M. et al. Aspirin Resistance. Adv Hematol 2009; PMID: 19960045.
  11. Deliargyris E.N., Boudoulas H. Aspirin Resistance. Hellenic J Cardiol 2004; 45: 1-5.
  12. Mangalpally K.K., Siqueiros-Garcia A., Vaduganathan M. et al. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis 2010; 30 (3): 251-262.
  13. Guthikonda S., Alviar C.L., Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (9): 743-749.
  14. Kunicki T.J., Williams S.A., Nugent D.J. et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101 (1): 123-133.
  15. Goodman T., Ferro A., Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66 (2): 222-232.
  16. Frelinger A.L., Furman M.I., Linden M.D. et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.
  17. Meen O., Brosstad F., Khiabani H. et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008; 68 (3): 185-191.
  18. Takahashi S., Ushida M., Komine R. et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121 (4): 509-517.
  19. Pettinella C., Romano M., Stuppia L. et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009; 101 (4): 687-690.
  20. Clappers N., Oijen M.G., Sundaresan S. et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008; 100 (1): 70-75.
  21. Chakroun T., Addad F., Yacoub S. et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. Genet Test Mol Biomarkers 2011; 15 (7-8): 513-516.
  22. Andrioli G., Minuz P., Solero P. et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911-918.
  23. Cooke G.E., Liu-Stratton Y., Ferketich A.K. et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47: 541-546.
  24. Lepantalo A., Mikkelsson J., Resendiz J. C. et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
  25. Lim E., Carballo S., Cornelissen J. et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl(A2) polymorphism (NCT00262275). Ann Thorac Surg 2007; 3: 134-138.
  26. Dropinski J., Musial J., Sanak M. et al. Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res 2007; 119: 301-303.
  27. Morawski W., Sanak M., Cisowski M. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791-796.
  28. Stepien E., Szuldrzynski K., Branicka A. et al. The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins. Pol Arch Med Wewn 2007; 117: 33-40.
  29. Undas A., Brummel K., Musial J. et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
  30. Fontana P., Nolli S., Reber G. et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-819.
  31. Lev E.I., Patel R.T., Guthikonda S. et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GPIIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119 (3): 355-360.
  32. Goodman T., Sharma P., Ferro A. The genetics of aspirin resistance. Int J Clin Pract 2007; 61: 826-834.
  33. Lordkipanidze M., Pharand C., Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
  34. Abderrazek F., Chakroun T., Addad F. et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 2010; 125 (6): 265-268.
  35. Syros G., Mehran R., Weisz G. et al. Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. Acute Card Care 2009; 11 (2): 88-91.
  36. Le Hello C., Morello R., Lequerrec A. et al. Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J 2007; 5: 19.
  37. Su G., Wang Z., Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci 2007; 27 (6): 664-667.
  38. Giusti B., Gori A. M., Marcucci R. et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008; 196 (1): 341-348.
  39. Zytkiewicz M., Giełwanowska L., Wojtasińska E. et al. Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008; 118 (12): 727-733.
  40. Gonzalez-Conejero R., Rivera J., Corral J. et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36 (2): 276-280.
  41. Pamukcu B., Oflaz H., Onur I. et al. Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood Coagul Fibrinolysis 2010; 21 (1): 53-56.
  42. Bernardo E., Angiolillo D. J., Ramírez C. et al. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17 (8): 586-590.
  43. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E. et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis Res 2005; 116 (6): 491-497.
  44. Godeneche G., Sorel N., Ragot S. et al. Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate. Platelets 2009; 20 (7): 471-477.
  45. Khaspekova S.G., Sirotkina O.V., Shimanova I.V. et al. Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action. Biomed Khim 2008; 54 (3): 361-371.
  46. Agúndez J.A., Martínez C., Pérez-Sala D. et al. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10 (9): 998-1008.
  47. Jin Y.Y., Yu G.Z., Wang Y. et al. Variable number of tandem repeats polymorphism of platelet glycoprotein Ib alpha in Chinese people and CC genotype with aspirin sensitivity in patients with cerebral infarction. J Clin Pharm Ther 2009; 34 (2): 239-243.
  48. Li Q., Chen B.L., Ozdemir V. et al. H. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8 (6): 577-586.
  49. Li X.L., Cao J., Fan L. et al. genetic polymorphisms of Ho-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients. Clin Appl Thromb Hemost 2012 [Epub ahead of print].
  50. Herrera-Galeano J.E., Becker D.M., Wilson A.F. et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregabili. Arterioscler Thromb Vasc Biol 2008; 28 (8): 1484-1490.
  51. McCaslin J., Ashour H., Bhattacharya V. et al. Increased platelet-monocyte aggregation in male claudicants with the Pl(A1/A2) polymorphism of Gp IIb/IIIa. Eur J Vasc Endovasc Surg 2008; 36 (2): 132-137.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies